Dietitians emptied Mounjaro after a 170% increase, while Wegovy Skyrocket 2,000% Skyrocket
Wegovy, a weight loss medicine, saw that sales in the UK has increased by 2,000 percent following a sudden passage of the British from rival Mounjaro. The switch, which is affected by Mounjaro’s 170% price increase, follows the plan to make accessible weight loss products by the British as part of the 10 -year health plan.
More information about consumer changes
Accordingly Weight loss program cheqapFor the first time, they reported that the interest from people who wanted to change the providers with a remarkable increase in users of weight loss injections was a sharp increase.
This trend is 27 times higher on Wednesday, an increase of 2,660% on Wednesday, with Wegovy sales last month.
The lowest dose sales also increased by 2.212%, which was attributed to the increasing awareness of Cheqep’s treatment and a renewed focus on health when the summer season ended.
The price of Wegovy starts at about £ 85 per month for the smallest dose and rises to £ 160 per month for the highest dose.
‘Wegovy will be popular’
According to Cheqap’s General Manager Toby Nicol, the company will pass other options of Wegovy and are sure that it will quickly become leading weight loss in the UK.
“Since the announcement of the price increase of Mounjaro last week, our Wegovy sales have exceeded all expectations since the announcement was announced.
He also stressed that the tendency reflects more than people who change people – represents new beginnings, individuals focused on their health more and more and more open to experimenting with the awareness.
‘Extraordinary growth in adoption of Wegovy has been seen from the existing Mounjaro patients who pass to Wegovy at higher doses of the drug in every dose of the drug, to new patients for the first time to new patients who started the lowest dosage weight loss journeys,’
What’s in Mounjaro’s price increase?
Eli Lilly announced an upright price increase for Mounjaro, a weight loss and diabetes injection in the UK-starting from the month of September, raising the highest dose cost at about £ 122 from £ 122 per month. Up to 170 %.
The company says that this regulation is compatible with other developed markets and responds to its pressure to reduce domestic drug costs. Particularly, NHS patients will not be affected by separate pricing agreements that protect public access.
However, private patients face significantly higher invoices – support concerns about welcome, stocking and expanding health inequalities.
Weight loss jabs in the UK
Recipes for GLP-1 weight loss drugs in the UK It almost doubled In 2023-24, from 1.4 million to 2024-25, NHS expenditures reached £ 269 million-about 2.4% of the pharmacy budget.
Currently more than 1.5 million people use injections such as Mounjaro and Wegovy, which are mostly online, and receive about 200,000 through NHS. Between UK womenMore than 10% already use GLP-1 treatments and 72% plan to try it in 2025, but almost a third citation stigma is a barrier.
As the demand for weight loss injections such as Wegovy and Mounjaro continues to fluctuate, the UK finds itself at the center of a rapidly changing health view. Increasing costs in the private sector, rising prescription rates and increasing public consciousness emphasize both the promises and difficulties of these treatments.
While many see them as strong tools to combat obesity, concerns remain on fair access, and long -term trust. When the use is expected to climb further, the debate is likely to intensify – it balances innovation and accessibility in the coming years against sustainable approaches to weight management.
